Genomma Lab Internacional, S.A.B. de C.V.

OTCPK:GNML.F Stock Report

Market Cap: US$1.2b

Genomma Lab Internacional. de Valuation

Is GNML.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GNML.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GNML.F ($1.27) is trading below our estimate of fair value ($1.91)

Significantly Below Fair Value: GNML.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GNML.F?

Key metric: As GNML.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GNML.F. This is calculated by dividing GNML.F's market cap by their current earnings.
What is GNML.F's PE Ratio?
PE Ratio15.3x
EarningsMex$1.60b
Market CapMex$24.58b

Price to Earnings Ratio vs Peers

How does GNML.F's PE Ratio compare to its peers?

The above table shows the PE ratio for GNML.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29.7x
PAHC Phibro Animal Health
54.9x60.0%US$961.2m
INVA Innoviva
18.5xn/aUS$1.2b
SUPN Supernus Pharmaceuticals
34.2x36.2%US$2.0b
COLL Collegium Pharmaceutical
11.2x22.0%US$1.0b
GNML.F Genomma Lab Internacional. de
15.3x19.8%US$24.6b

Price-To-Earnings vs Peers: GNML.F is good value based on its Price-To-Earnings Ratio (15.3x) compared to the peer average (29.6x).

Price to Earnings Ratio vs Industry

How does GNML.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

8 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NDOI Endo
0.5xn/aUS$1.78b
KPRX Kiora Pharmaceuticals
1.9x-40.4%US$10.35m
EDXC Endexx
0.9xn/aUS$6.03m
CNNC Cannonau
0.7xn/aUS$241.82k
GNML.F 15.3xIndustry Avg. 19.8xNo. of Companies8PE01224364860+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GNML.F is good value based on its Price-To-Earnings Ratio (15.3x) compared to the US Pharmaceuticals industry average (19.3x).

Price to Earnings Ratio vs Fair Ratio

What is GNML.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GNML.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.3x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate GNML.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GNML.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.27
US$1.29
+1.5%
18.4%US$1.64US$0.89n/a6
Nov ’25n/a
US$1.29
0%
18.4%US$1.64US$0.89n/a6
Oct ’25US$1.13
US$1.17
+3.3%
16.6%US$1.42US$0.91n/a7
Sep ’25US$0.98
US$1.12
+14.7%
16.0%US$1.46US$0.90n/a7
Aug ’25n/a
US$1.12
0%
16.0%US$1.46US$0.90n/a7
Jul ’25n/a
US$1.10
0%
15.6%US$1.41US$0.90n/a6
Jun ’25n/a
US$1.13
0%
14.5%US$1.45US$0.93n/a7
May ’25n/a
US$1.13
0%
14.5%US$1.45US$0.93n/a7
Apr ’25US$0.97
US$1.23
+26.7%
12.4%US$1.46US$1.05n/a7
Mar ’25US$0.81
US$1.23
+50.8%
12.4%US$1.46US$1.05n/a7
Feb ’25n/a
US$1.27
0%
12.1%US$1.45US$1.05n/a6
Jan ’25n/a
US$1.27
0%
12.1%US$1.45US$1.05n/a6
Dec ’24n/a
US$1.27
0%
12.1%US$1.45US$1.05n/a6
Nov ’24n/a
US$1.21
0%
11.6%US$1.38US$0.99n/a6
Oct ’24US$0.81
US$1.19
+46.7%
15.1%US$1.43US$0.97US$1.137
Sep ’24n/a
US$1.26
0%
14.9%US$1.49US$1.01US$0.987
Aug ’24n/a
US$1.25
0%
14.3%US$1.42US$1.01n/a7
Jul ’24n/a
US$1.17
0%
11.1%US$1.30US$0.97n/a7
Jun ’24US$0.82
US$1.17
+42.1%
11.1%US$1.30US$0.97n/a7
May ’24n/a
US$1.17
0%
11.1%US$1.30US$0.97n/a7
Apr ’24n/a
US$1.17
0%
11.1%US$1.30US$0.97US$0.977
Mar ’24US$0.83
US$1.24
+49.1%
10.6%US$1.41US$0.98US$0.816
Feb ’24n/a
US$1.23
0%
11.0%US$1.38US$0.96n/a6
Jan ’24n/a
US$1.20
0%
11.4%US$1.32US$0.91n/a6
Dec ’23US$0.76
US$1.23
+60.5%
12.8%US$1.46US$0.91n/a7
Nov ’23US$0.78
US$1.23
+57.9%
12.8%US$1.46US$0.91n/a7

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Collegium Pharmaceutical

US$1.0b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

7D

2.4%

1Y

20.0%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$59.39

7D

7.8%

1Y

20.6%

Teva Pharmaceutical Industries

US$18.8b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.57

7D

-2.7%

1Y

71.0%